Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Decibel Therapeutics, Inc. DBTX
$3.84
+$0.36 (9.40%)
На 18:04, 12 мая 2023
Ранг: 3
Ключевые показатели
-
Marketcap
83800250.00000000
-
week52high
5.78
-
week52low
1.61
-
Revenue
0
-
P/E TTM
-1
-
Beta
-0.13849300
-
EPS
-2.34000000
-
Last Dividend
0.00000000
-
Next Earnings Date
10 мая 2023 г. в 12:30
Описание компании
Decibel Therapeutics, Inc., a clinical-stage biotechnology company, engages in discovering and developing transformative treatments for hearing and balance disorders. Its product candidates and programs focuses on three areas, such as Gene Therapies for Congenital, Monogenic Hearing Loss designed to restore functional cells within the cochlea to address hearing disorders caused by single gene mutations; Gene Therapies for Hair Cell Regeneration designed to replace lost hair cells within the inner ear to address acquired hearing loss and balance disorders; and Otoprotection Therapeutic in clinical development to prevent hearing loss in cancer patients undergoing chemotherapy with cisplatin. The company's lead gene therapy product candidate is DB-OTO to provide hearing to individuals born with profound hearing loss due to mutation of the otoferlin gene. It is also developing DB-ATO and AAV.201, a gene therapy program designed to restore balance in patients with bilateral vestibulopathy by regenerating lost hair cells within the vestibule; DB-020 for the prevention of cisplatin-induced hearing loss, which is in Phase 1b clinical trial; AAV.103 to restore hearing in individuals with a gap junction beta-2 (GJB2) deficiency; AAV.104 to restore hearing in individuals with stereocilin (STRC) deficiency; and cochlear hair cell regeneration program, an AAV-based gene therapy that utilizes cell-selective expression of reprogramming factors to convert supporting cells into outer hair cells. Decibel Therapeutics, Inc. has a strategic collaboration with Regeneron Pharmaceuticals, Inc. to develop gene therapies for monogenic forms of congenital hearing loss. The company was formerly known as Hearing Inc. and changed its name to Decibel Therapeutics, Inc. in April 2014. Decibel Therapeutics, Inc. was incorporated in 2013 and is headquartered in Boston, Massachusetts.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Citigroup | Buy | Buy | 17 мая 2022 г. |
| Barclays | Overweight | Overweight | 21 мар 2022 г. |
| JonesTrading | Buy | 02 дек 2021 г. | |
| HC Wainwright & Co. | Buy | 15 ноя 2021 г. | |
| SVB Leerink | Outperform | Outperform | 10 ноя 2021 г. |
| Citigroup | Buy | Buy | 10 ноя 2022 г. |
| SVB Leerink | Outperform | Outperform | 23 янв 2023 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Trask Anna | A | 45000 | 45000 | 26 янв 2023 г. |
| Trask Anna | A | 106864 | 105000 | 26 янв 2023 г. |
| Lee John Jui-Jen | A | 45000 | 45000 | 26 янв 2023 г. |
| Lee John Jui-Jen | A | 147144 | 120000 | 26 янв 2023 г. |
| MCLAUGHLIN KEVIN F | A | 20000 | 20000 | 10 окт 2022 г. |
| Thompson Peter A. | A | 10000 | 10000 | 17 июн 2022 г. |
| Carson William H. | A | 10000 | 10000 | 17 июн 2022 г. |
| FINGER ALISON CECILY | A | 10000 | 10000 | 17 июн 2022 г. |
| Nochur Sara | A | 10000 | 10000 | 17 июн 2022 г. |
| Exter Neil | A | 10000 | 10000 | 17 июн 2022 г. |
Новостная лента
Decibel Therapeutics to Participate in Upcoming Investor Conferences
GlobeNewsWire
31 авг 2022 г. в 07:00
BOSTON, Aug. 31, 2022 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced that Laurence Reid, Ph.D., Chief Executive Officer, will be participating in the following upcoming investor conferences in September.
Top Penny Stocks Today? 3 You Might Want To Watch Before Next Week
PennyStocks
29 июн 2022 г. в 13:28
Penny stocks to watch before the end of the week. The post Top Penny Stocks Today?
Decibel Therapeutics Delivers Solid Interim Data From Cisplatin-Associated Hearing Loss Study
Benzinga
28 июн 2022 г. в 15:38
Decibel Therapeutics Inc (NASDAQ: DBTX) reported positive top-line results from an interim analysis of its ongoing Phase 1b clinical trial of DB-020 to protect against hearing loss in cancer patients receiving cisplatin chemotherapy. The interim analysis showed that 88% of.
Decibel Therapeutics to Present at the Jefferies Global Healthcare Conference
GlobeNewsWire
03 июн 2022 г. в 07:30
BOSTON, June 03, 2022 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced that John Lee, chief development officer, and Lis Leiderman, M.D., MBA, chief financial officer, will participate in a fireside chat at the Jefferies Global Healthcare Conference on Friday, June 10, 2022 at 9:00 a.m. ET.
Decibel Therapeutics to Present at the H.C. Wainwright Global Investment Conference
GlobeNewsWire
17 мая 2022 г. в 07:30
BOSTON, May 17, 2022 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced that Laurence Reid, Ph.D., Chief Executive Officer of Decibel, will participate in a fireside chat at the H.C. Wainwright Global Investment Conference. The fireside chat will be available for on-demand viewing starting Tuesday, May 24, 2022 at 7:00 a.m. E.T.